FDA Grants Breakthrough Therapy Designation to Huahui Health’s Libevitug (HH-003) for treatment of chronic Hepatitis D virus infection

BEIJING, Nov. 18, 2024 /PRNewswire/ — Huahui Health, a clinical-stage biotechnology company focused on discovering and developing novel therapies in the areas of viral hepatitis, hepatology, and oncology, today announced that its investigational hepatitis D and B drug candidate,…